Reviewer	Employment	Research Grant	Other Research Support	Speakers’ Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Chris Denning	University of Nottingham (United Kingdom)	None	None	None	None	None	None	None
Mitchell S. Elkind	Columbia University	NINDS (NOMAS grant on stroke incidence and risk factors)†; Biogen (PI of clinical trial)*	BMS-Pfizer Alliance for Eliquis (support in kind for stroke trial)†; Roche (support in kind for a trial of stroke)†	None	Merck/Organon†; Auxilium†; LivaNova (Sorin)†	None	Abbott*; Vascular Dynamics*; Medtronic*
Raj Kishore	Temple University	None	None	None	None	None	None	None
Martin Traebert	Preclinical Safety (Switzerland)	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

^*

Modest

^†

Significant.